Literature DB >> 31317422

Subtypes in eosinophilic granulomatosis with polyangiitis classified according to rheumatoid factor.

Jun Inamo1, Yuko Kaneko2, Yuichiro Ota1, Tsutomu Takeuchi1.   

Abstract

To investigate the relevance of RF in patients with EGPA, we reviewed consecutive patients who were newly diagnosed with EGPA from August 1998 to February 2019 in Keio University Hospital with RF titer at diagnosis available. We divided the patients according to the median level of RF titer of 75 IU/mL and compared clinical features between the two groups. Among 16 patients identified, 8 patients were in the RF high group and the other 8 patients were in the RF low group. All patients in the high RF group were negative for MPO-ANCA, whereas all in the low RF group was positive for MPO-ANCA with a mean titer of 103 IU/mL. The eosinophil count at diagnosis was significantly higher in the RF high group than the RF low group (20001/μL vs 5144/μL, p < 0.01). Gastrointestinal lesion was significantly more frequent in the RF high group, and parenchymal organ lesions, such as heart and renal organ involvement, were frequent in the RF low group. With principal component analysis, RF high and low groups were clearly divided by the combination of eosinophil count, MPO-ANCA titer, gastrointestinal lesions, musculoskeletal symptoms, and disease activity score. Those results suggest EGPA can be divided into two groups in association with RF.Key Points• Our study showed that patients with EGPA can be separated into two groups according to RF titer.• The two subtypes reflect different underlying pathogenesis in EGPA, and the optimal treatment for them may be different.

Entities:  

Keywords:  Antineutrophil cytoplasmic auto-antibodies-associated vasculitis; Biomarker; Eosinophilic granulomatosis with polyangiitis; Rheumatoid factor

Mesh:

Substances:

Year:  2019        PMID: 31317422     DOI: 10.1007/s10067-019-04680-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  Correlation between rheumatoid factor and peripheral eosinophil count in chronic eosinophilic pneumonia.

Authors:  Megumi Kudou; Hirotaka Yasuba; Yoshiki Kobayashi; Kazuyuki Hamada; Hideo Kita
Journal:  Respirology       Date:  2006-11       Impact factor: 6.424

Review 2.  Genetics of ANCA-associated vasculitides: HLA and beyond.

Authors:  Federico Alberici; Davide Martorana; Francesco Bonatti; Andrea Gioffredi; Paul A Lyons; Augusto Vaglio
Journal:  Clin Exp Rheumatol       Date:  2014-05-15       Impact factor: 4.473

3.  Autoantibody profiles and their association with blood eosinophils in asthma and COPD.

Authors:  Koji Tamai; Harukazu Yoshimatsu; Toshiharu Saito; Hirofumi Matsuoka; Nobuhiko Okada; Yasuko Koma; Akiko Otsuka; Nao Oda; Sayaka Inoue; Sachie Kume; Yujiro Suzuki
Journal:  Allergol Int       Date:  2016-08-31       Impact factor: 5.836

4.  Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.

Authors:  Renato A Sinico; Lucafrancesco Di Toma; Umberto Maggiore; Paolo Bottero; Antonella Radice; Cinzia Tosoni; Chiara Grasselli; Laura Pavone; Gina Gregorini; Stefano Monti; Micol Frassi; Filomena Vecchio; Caterina Corace; Emanuela Venegoni; Carlo Buzio
Journal:  Arthritis Rheum       Date:  2005-09

5.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.

Authors:  Richard Watts; Suzanne Lane; Thomas Hanslik; Thomas Hauser; Bernhard Hellmich; Wenche Koldingsnes; Alfred Mahr; Mårten Segelmark; Jan W Cohen-Tervaert; David Scott
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

6.  Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome.

Authors:  Régis Sablé-Fourtassou; Pascal Cohen; Alfred Mahr; Christian Pagnoux; Luc Mouthon; David Jayne; Daniel Blockmans; Jean-François Cordier; Philippe Delaval; Xavier Puechal; Dominique Lauque; Jean-François Viallard; Abdelkader Zoulim; Loïc Guillevin
Journal:  Ann Intern Med       Date:  2005-11-01       Impact factor: 25.391

7.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

8.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.

Authors:  Cloé Comarmond; Christian Pagnoux; Mehdi Khellaf; Jean-François Cordier; Mohamed Hamidou; Jean-François Viallard; François Maurier; Stéphane Jouneau; Boris Bienvenu; Xavier Puéchal; Olivier Aumaître; Guillaume Le Guenno; Alain Le Quellec; Ramiro Cevallos; Olivier Fain; Bertrand Godeau; Raphaèle Seror; Bertrand Dunogué; Alfred Mahr; Philippe Guilpain; Pascal Cohen; Achille Aouba; Luc Mouthon; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2013-01

9.  Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia.

Authors:  Edmond Sarkis; Sumit Patel; Kenneth Burns; Hanan Batarseh; M Jeffery Mador
Journal:  J Asthma       Date:  2018-11-16       Impact factor: 2.515

Review 10.  Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.

Authors:  William Busse; Geoffrey Chupp; Hiroyuki Nagase; Frank C Albers; Scott Doyle; Qin Shen; Daniel J Bratton; Necdet B Gunsoy
Journal:  J Allergy Clin Immunol       Date:  2018-09-08       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.